Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Trends in thrombolytic use for ischemic stroke in the United States.

Fang MC, Cutler DM, Rosen AB.

J Hosp Med. 2010 Sep;5(7):406-9. doi: 10.1002/jhm.689.

2.
3.

Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2014 Apr 23-30;311(16):1632-40. doi: 10.1001/jama.2014.3203.

PMID:
24756513
4.

Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.

Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):543-9. doi: 10.1161/CIRCOUTCOMES.111.000303.

5.

Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity.

Johnston SC, Fung LH, Gillum LA, Smith WS, Brass LM, Lichtman JH, Brown AN.

Stroke. 2001 May;32(5):1061-8.

6.

Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.

Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL; German Stroke Registers Study Group.; Competence Net Stroke..

Stroke. 2003 May;34(5):1106-13.

7.

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2013 Jun 19;309(23):2480-8. doi: 10.1001/jama.2013.6959.

PMID:
23780461
8.

United States trends in thrombolysis for older adults with acute ischemic stroke.

George BP, Asemota AO, Dorsey ER, Haider AH, Smart BJ, Urrutia VC, Schneider EB.

Clin Neurol Neurosurg. 2015 Dec;139:16-23. doi: 10.1016/j.clineuro.2015.08.031.

PMID:
26363362
9.

Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-Thrombolysis: Findings From Get With The Guidelines-Stroke.

Masrur S, Cox M, Bhatt DL, Smith EE, Ellrodt G, Fonarow GC, Schwamm L.

J Am Heart Assoc. 2015 Sep 25;4(10):e002193. doi: 10.1161/JAHA.115.002193.

11.

Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences?

Allen NB, Myers D, Watanabe E, Dostal J, Sama D, Goldstein LB, Lichtman JH.

Cerebrovasc Dis. 2009;27(3):254-8. doi: 10.1159/000196824.

PMID:
19176959
12.

Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.

Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, Ikeda Y, Matsuura T, Narai H, Omori N, Manabe Y, Yunoki T, Takao Y, Kawata S, Kashihara K, Abe K.

J Stroke Cerebrovasc Dis. 2013 Apr;22(3):190-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.016.

PMID:
21968092
13.

Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive.

Saposnik G, Reeves MJ, Johnston SC, Bath PM, Ovbiagele B; VISTA Collaboration..

Stroke. 2013 Oct;44(10):2755-9. doi: 10.1161/STROKEAHA.113.001343.

14.

The use and misuse of thrombolytic therapy within the Veterans Health Administration.

Keyhani S, Arling G, Williams LS, Ross JS, Ordin DL, Myers J, Tyndall G, Vogel B, Bravata DM.

Med Care. 2012 Jan;50(1):66-73. doi: 10.1097/MLR.0b013e3182294092.

PMID:
22182924
15.

Bigger, faster? Associations between hospital thrombolysis volume and speed of thrombolysis administration in acute ischemic stroke.

Bray BD, Campbell J, Cloud GC, Hoffman A, Tyrrell PJ, Wolfe CD, Rudd AG; Intercollegiate Stroke Working Party Group..

Stroke. 2013 Nov;44(11):3129-35. doi: 10.1161/STROKEAHA.113.001981. Erratum in: Stroke. 2013 Nov;44(11):162.

16.

Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke.

Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA.

J Stroke Cerebrovasc Dis. 2013 Feb;22(2):154-60. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.003.

PMID:
22155116
17.

Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.

Power A, Epstein D, Cohen D, Bathula R, Devine J, Kar A, Taube D, Duncan N, Ames D.

Cerebrovasc Dis. 2013;35(1):45-52. doi: 10.1159/000345071.

PMID:
23428996
18.

Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.

Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J, Hermanek P, Leffmann C, Sitzer M, Biegler M, Buecker-Nott HJ, Berger K; German Stroke Registers Study Group..

JAMA. 2004 Oct 20;292(15):1831-8.

PMID:
15494580
19.

Determinants of early outcomes in patients with acute ischemic stroke and proximal artery occlusion.

LaBuzetta JN, Yoo AJ, Ali S, Fitzpatrick K, Leslie-Mazwi T, Hirsch JA, Schwamm L, Rost N.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2527-32. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.020.

20.

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.

Lin CB, Cox M, Olson DM, Britz GW, Constable M, Fonarow GC, Schwamm L, Peterson ED, Shah BR.

J Am Heart Assoc. 2015 Jul 22;4(7). pii: e001298. doi: 10.1161/JAHA.114.001298.

Supplemental Content

Support Center